- /
- Supported exchanges
- / US
- / PROK.NASDAQ
ProKidney Corp. (PROK NASDAQ) stock market data APIs
ProKidney Corp. Financial Data Overview
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with ProKidney Corp. (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get ProKidney Corp. data using free add-ons & libraries
Get ProKidney Corp. Fundamental Data
ProKidney Corp. Fundamental data includes:
- Net Revenue: 775 K
- EBITDA: -185 907 008
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-12
- EPS/Forecast: -0.13
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ProKidney Corp. News
New
ProKidney Corp. (PROK) Reports Q3 Loss, Misses Revenue Estimates
ProKidney Corp. (PROK) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.12 per share a year ago. These figures ar...
ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights
ProKidney On track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint (eGFR slope) topline results in Q2 2027 Anticipate completing full enrollment for the PROACT 1 confirmatory analysis in Q1 20...
Merck KGaA (MKKGY) Lags Q3 Earnings Estimates
Merck KGaA (MKKGY) came out with quarterly earnings of $0.24 per share, missing the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.81 per share a year ago. These figures a...
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Beats Revenue Estimates
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.12 per share a year ago. These figur...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.